UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Protein expression profiling identifies differential modulation of homologous recombination by platinum-based antitumor agents

Cancer chemotherapy and pharmacology, 2020-06, Vol.85 (6), p.1129-1140

2020

Link zum Volltext

Verfügbarkeit prüfen

Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents

Proceedings of the National Academy of Sciences - PNAS, 2020-03, Vol.117 (13), p.7021-7029

2020

Link zum Volltext

Verfügbarkeit prüfen

Functional Activation of Mutant p53 by Platinum Analogues in Cisplatin-Resistant Cells Is Dependent on Phosphorylation

Molecular cancer research, 2017-03, Vol.15 (3), p.328-339

2017

Link zum Volltext

Verfügbarkeit prüfen

Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity

Clinical cancer research, 2021-01, Vol.27 (2), p.542-553

2021

Link zum Volltext

Verfügbarkeit prüfen

Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities

Oncogene, 2005-04, Vol.24 (18), p.2929-2943

2005

Link zum Volltext

Verfügbarkeit prüfen

Tissue Platinum Concentration and Tumor Response in Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2012-09, Vol.30 (27), p.3345-3352

2012

Link zum Volltext

Verfügbarkeit prüfen

Biologic Effects of Dopamine on Tumor Vasculature in Ovarian Carcinoma

Neoplasia (New York, N.Y.), 2013-05, Vol.15 (5), p.502-IN15

2013

Link zum Volltext

Verfügbarkeit prüfen

Regulation of Cdc25C by ERK-MAP Kinases during the G2/M Transition

Cell, 2007-03, Vol.128 (6), p.1119-1132

2007

Link zum Volltext

Verfügbarkeit prüfen

Corrigendum to “PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis” [EBioMedicine 40 (2019) 290-304]

EBioMedicine, 2022-09, Vol.83, p.104194-104194, Article 104194

2022

Link zum Volltext

Verfügbarkeit prüfen

Involvement of the Conserved Adaptor Protein Alix in Actin Cytoskeleton Assembly

The Journal of biological chemistry, 2006-11, Vol.281 (45), p.34640-34650

2006

Link zum Volltext

Verfügbarkeit prüfen

Protein kinase inhibitors emodin and dichloro-ribofuranosylbenzimidazole modulate the cellular accumulation and cytotoxicity of cisplatin in a schedule-dependent manner

Cancer chemotherapy and pharmacology, 2010-02, Vol.65 (3), p.427-436

2010

Link zum Volltext

Verfügbarkeit prüfen

The Role of p27Kip1 in Dasatinib-Enhanced Paclitaxel Cytotoxicity in Human Ovarian Cancer Cells

JNCI : Journal of the National Cancer Institute, 2011-08, Vol.103 (18), p.1403-1422

2011

Link zum Volltext

Verfügbarkeit prüfen

Comparative activity of TiO2 microspheres and P25 powder for organic degradation: Implicative importance of structural defects and organic adsorption

Applied surface science, 2014-11, Vol.319, p.2-7

2014

Link zum Volltext

Verfügbarkeit prüfen

Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill

Molecular pharmacology, 2020-04, Vol.97 (4), p.237-249

2020

Link zum Volltext

Verfügbarkeit prüfen

Alternative assessment of nano-TiO2 sedimentation under different conditions based on sedimentation efficiency at quasi-stable state

Journal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology, 2015-11, Vol.17 (11), p.1, Article 454

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract P053: VAL-083 (dianhydrogalactitol) synergizes with PARP inhibitors in BRCA-proficient and BRCA-deficient ovarian cancer models

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.P053-P053

2021

Link zum Volltext

Verfügbarkeit prüfen

Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator

Angewandte Chemie (International ed.), 2016-10, Vol.55 (41), p.12626-12631

International ed. in English, 2016

Link zum Volltext

Verfügbarkeit prüfen

Functional activation of mutant p53V172F by platinum analogs in cisplatin-resistant human tumor cells is dependent on serine-20 phosphorylation

Molecular cancer research, 2016-12, Vol.15 (3), p.328-339

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract NT-109: VAL-083 (DIANHYDROGALACTITOL) SYNERGIZES WITH PARP INHIBITORS IN BRCA-PROFICIENT AND BRCA-DEFICIENT OVARIAN CANCER MODELS

Clinical cancer research, 2019-11, Vol.25 (22_Supplement), p.NT-109-NT-109

2019

Link zum Volltext

Verfügbarkeit prüfen

Oxaliplatin Pt(IV) prodrugs conjugated to gadoliniumtexaphyrin as potential antitumor agents

Proceedings of the National Academy of Sciences - PNAS, 2020-03, Vol.117 (13), p.7021-7029

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1073: Preclinical tissue biodistribution and plasma pharmacokinetic studies with oxaliTEX, a novel platinum(IV)-based oxaliplatin prodrug

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1073-1073

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract A01: Distinct mechanism of action of DNA-damaging agent dianhydrogalactitol (VAL-083) suggests combination therapy with PARP inhibitors

Clinical cancer research, 2018-08, Vol.24 (15_Supplement), p.A01-A01

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1962: Dianhydrogalactitol (VAL-083) has a distinct mechanism of action that suggests combination with PARP inhibitors as an effective therapeutic strategy

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1962-1962

2018

Link zum Volltext

Verfügbarkeit prüfen

Dominating Role of Ionic Strength in the Sedimentation of Nano-TiO2 in Aquatic Environments

Journal of nanomaterials, 2015-01, Vol.2015

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract A109: DNA-damaging agent dianhydrogalactitol (VAL-083) targets HR repair pathway and suggests combination therapy with topoisomerase and PARP inhibitors

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.A109-A109

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 497

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(474)
Mit Volltextzugriff
(491)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(367)
Technology
(263)
Materials Science
(173)
Physical Sciences
(147)
Engineering
(110)
Materials Science, Multidisciplinary
(100)
Physics
(98)
Tribology
(91)
Physics, Applied
(76)
Engineering, Mechanical
(69)
Life Sciences & Biomedicine
(59)
Chemistry
(58)
Friction
(55)
Materials Science, Coatings & Films
(52)
Mechanical Properties
(48)
Humans
(43)
Coefficient Of Friction
(42)
Diamond-Like Carbon Films
(37)
Physics, Condensed Matter
(37)
Science & Technology - Other Topics
(35)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Protein expression profiling identifies differential modulation of homologous recombination by platinum-based antitumor agents

Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents

Functional Activation of Mutant p53 by Platinum Analogues in Cisplatin-Resistant Cells Is Dependent on Phosphorylation

Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity

Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities

Tissue Platinum Concentration and Tumor Response in Non–Small-Cell Lung Cancer

Biologic Effects of Dopamine on Tumor Vasculature in Ovarian Carcinoma

Regulation of Cdc25C by ERK-MAP Kinases during the G2/M Transition

Corrigendum to “PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis” [EBioMedicine 40 (2019) 290-304]

Involvement of the Conserved Adaptor Protein Alix in Actin Cytoskeleton Assembly

Protein kinase inhibitors emodin and dichloro-ribofuranosylbenzimidazole modulate the cellular accumulation and cytotoxicity of cisplatin in a schedule-dependent manner

The Role of p27Kip1 in Dasatinib-Enhanced Paclitaxel Cytotoxicity in Human Ovarian Cancer Cells

Comparative activity of TiO2 microspheres and P25 powder for organic degradation: Implicative importance of structural defects and organic adsorption

Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill

Alternative assessment of nano-TiO2 sedimentation under different conditions based on sedimentation efficiency at quasi-stable state

Abstract P053: VAL-083 (dianhydrogalactitol) synergizes with PARP inhibitors in BRCA-proficient and BRCA-deficient ovarian cancer models

Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator

Functional activation of mutant p53V172F by platinum analogs in cisplatin-resistant human tumor cells is dependent on serine-20 phosphorylation

Abstract NT-109: VAL-083 (DIANHYDROGALACTITOL) SYNERGIZES WITH PARP INHIBITORS IN BRCA-PROFICIENT AND BRCA-DEFICIENT OVARIAN CANCER MODELS

Oxaliplatin Pt(IV) prodrugs conjugated to gadoliniumtexaphyrin as potential antitumor agents

Abstract 1073: Preclinical tissue biodistribution and plasma pharmacokinetic studies with oxaliTEX, a novel platinum(IV)-based oxaliplatin prodrug

Abstract A01: Distinct mechanism of action of DNA-damaging agent dianhydrogalactitol (VAL-083) suggests combination therapy with PARP inhibitors

Abstract 1962: Dianhydrogalactitol (VAL-083) has a distinct mechanism of action that suggests combination with PARP inhibitors as an effective therapeutic strategy

Dominating Role of Ionic Strength in the Sedimentation of Nano-TiO2 in Aquatic Environments

Abstract A109: DNA-damaging agent dianhydrogalactitol (VAL-083) targets HR repair pathway and suggests combination therapy with topoisomerase and PARP inhibitors

Suchergebnisse filtern